insulin/GLP-1 nanoparticles (MidaSol Therapeutics)

N/A

Report date: 2026/05/12 20:00:17

Base Information

Drug Nameinsulin/GLP-1 nanoparticles (MidaSol Therapeutics)
Drug Alias Nameinsulin/GLP-1 nanoparticles (MonoSol/Midatech)MidaForm insulin/GLP-1 nanoparticle
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionInsulin receptor agonistsInsulin ligandGlucagon-like peptide 1 receptor agonists
TargetsInsulin receptorGlucagon-like peptide 1 receptor
Therapy Area/IndicationsDiabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBiodexa Pharmaceuticals PLC
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiodexa Pharmaceuticals PLCAquestive Therapeutics Inc +[3] 
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus

Other Information

ATC CodeN/A
Related LinksN/A